Design and Validation of a Biomarker-enhanced System to Predict RCC Progression

预测 RCC 进展的生物标志物增强系统的设计和验证

• 批准号: 8207268
• 负责人: ALEXANDER S PARKER
• 金额: $ 38万
• 依托单位: MAYO CLINIC JACKSONVILLE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8207268
• 关键词: Abdomen; Adjuvant; Adjuvant Therapy; Algorithms; American Cancer Society; Archives; Biological Markers; Biology; Cancer Center; Cell Line; Cessation of life; Characteristics; Clear Cell; Clinic; Clinical; Clinical Data; Clinical Trials; Clinical Trials Design; Diagnosis; Diagnostic Neoplasm Staging; Disease; Disease Progression; Distant Metastasis; Drops; Ensure; Evaluation; Excision; Future; Generations; Genomics; Goals; Hand; Image; Incidence; Individual; Institution; Intervention; Investigation; KOC1 gene; Kidney; Localized Disease; Malignant Epithelial Cell; Malignant Neoplasms; Malignant neoplasm of urinary bladder; Measures; Metastatic to; Methods; Molecular; National Cancer Institute; Necrosis; Neoplasm Metastasis; Nephrectomy; Operative Surgical Procedures; Organ; Outcome; Pathogenesis; Pathologic; Patients; Population; Postoperative Period; Primary Neoplasm; Prognostic Factor; Progress Review Group; Publishing; Recurrence; Renal Cell Carcinoma; Reporting; Resources; Review Literature; Risk; Sampling; Site; Staining method; Stains; Stratification; System; Testing; Therapeutic; Therapeutic Intervention; Time; Tissue Sample; Tissues; Translations; Tumor Tissue; Tumor stage; Validation; Work; base; cancer recurrence; cohort; combinatorial; design; experience; high risk; improved; indexing; interest; member; mortality; novel; novel therapeutics; patient population; patient registry; prognostic; response; success; survivin; tool; trend; tumor

PROJECT/SUMMARY ABSTRACT Incidence rates for renal cell carcinoma (RCC) have risen steadily over the past three decades, with the majority of this increase seen among localized tumors. Hallmark features of RCC include a predominance of clear cell subtype (ccRCC), a variable clinical course, and limited treatment options beyond surgical excision. Of interest, approximately 35% of patients treated surgically for localized ccRCC will experience disease progression (i.e. develop distant metastases) and most of these will occur within one year of surgery. Related to this, in 2003 we published the Mayo Clinic Progression (PROG) Score, an algorithm that is used to help predict which ccRCC patients will progress after surgery. While the PROG score has demonstrable prognostic value for patients with localized ccRCC, it is based entirely on information from pathologic indices and therefore represents only a surrogate measure of the underlying molecular characteristics that ultimately determine tumor aggressiveness. As such, the PROG score does not provide complete patient stratification nor does it inform on the biology of ccRCC aggressiveness or identify potential targets for therapeutic intervention. These limitations underscore the need to identify molecular prognostic factors that, in isolation or in combination with existing prognostic tools, not only improve prediction of ccRCC progression but also provide potential targets for clinical intervention. In direct response to this need, members of our investigative team employed a variety of discovery methods to identify a panel of seven tumor-based biomarkers of ccRCC aggressiveness (survivin, B7-H1, B7-H4, Ki-67, IGF-IR, IMP3 and CA-IX). More importantly, we have published individual preliminary investigations showing that tumor expression levels of each of these biomarkers are associated with an increased risk of ccRCC progression following surgery for localized disease. Herein, we propose to continue the translation of our biomarker discovery efforts by (1) generating a novel biomarker-based scoring algorithm to predict ccRCC progression, which when integrated with our existing PROG score will result in a more robust and accurate scoring system (BioPROG); (2) externally validating the prognostic value of this new scoring system in two independent populations of ccRCC patients and (3) exploring for the first time the expression of our seven biomarkers in metastatic ccRCC tissues and examining their ability to predict time to death following diagnosis of metastatic disease. To do this, we propose to harness high-quality clinical data and biospecimen resources available through ongoing large patient registries at our institutions. In summation, our overarching goal is to improve prognostic stratification following surgery for patients with localized ccRCC as well as inform on the underlying biology of ccRCC progression. This effort will ultimately enhance patient management/surveillance, allow for more appropriate clinical trial design, inform the molecular underpinnings of ccRCC pathogenesis, provide the rationale for novel therapeutic strategies, and represent a logical platform for the evaluation of patient response to emerging adjuvant therapeutics.

项目/总结抽象